[ad_1]
According to a recent filing with the SEC, Sadie Stern, executive vice president and chief human resources officer at DexCom Inc (DXCM, Financials), sold 4,137 shares of the company’s stock on March 25, 2024. The average price of the transaction was $140 per share, for a total value of $578,180.
DexCom Inc is a medical device company focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for patients with diabetes. These systems are designed to help patients manage blood sugar levels by providing real-time blood glucose readings, trending information and alerts that warn users of potential hypoglycemia or hyperglycemia.
In the past year, Sadie Stern sold a total of 30,891 shares of DexCom Inc and did not purchase any shares. Recent sales by insiders have contributed to the overall insider selling trend observed at the company.
DexCom Inc’s insider trading history shows a selling pattern, with 0 insider purchases and 52 insider sales over the past year.
In terms of valuation, on the day of the insider sales, DexCom Inc’s share price was $140, giving the company a market capitalization of $53.945 billion. The price-to-earnings ratio is 106.82, which is higher than the industry median of 27.57, but lower than the company’s historical price-to-earnings ratio median.
The stock’s P/E ratio currently stands at 0.89 and its GF value is $157.14, indicating that DexCom Inc is moderately undervalued based on GuruFocus’s intrinsic value estimates. GF values ββare calculated based on historical trading multiples, GuruFocus adjustment factors, and Morningstar analyst estimates of future business performance.
Investors and analysts often monitor insider sales because it can provide insight into what insiders think about the value of a company’s shares. While insider trading does not necessarily indicate a lack of confidence in a company, it can prompt market participants to consider the underlying reasons behind the trade.
It’s important to note that insider trading can be influenced by a variety of factors, including personal investment diversification, tax planning and other personal financial considerations. Therefore, investors should consider the broader market context, company performance, and other metrics when evaluating insider transactions.
This article was generated by GuruFocus and is intended to provide general insight and is not tailored financial advice. Our commentary is rooted in historical data and analyst forecasts, employs an unbiased methodology, and is not intended to serve as specific investment guidance. It does not make a recommendation to purchase or divest any stock and does not take into account personal investment objectives or financial situation. Our goal is to provide long-term, fundamental data-driven analysis. Please note that our analysis may not include the latest, price-sensitive company announcements or qualitative information. GuruFocus does not hold a position in the stocks mentioned in this article.
[ad_2]
Source link